House dust mite allergy immunotherapy - Allergy Therapeutics

Drug Profile

House dust mite allergy immunotherapy - Allergy Therapeutics

Alternative Names: Acarovac; Acarovac Plus; HDM allergy vaccine - Allergy Therapeutics; House dust mite allergy vaccine - Allergy Therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Allergy Therapeutics
  • Class Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in United Kingdom (SC)
  • 01 Mar 2013 Launched for Allergic rhinitis in Spain (SC)
  • 01 Mar 2013 Acarovac Plus is available on a Named Patient Access Programme for the treatment of allergic rhinitis in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top